Neuraxpharm Group, a leading European specialty pharmaceutical company focused on central nervous system (CNS) disorders, and Swedish R&D firm Dizlin Pharmaceuticals AB have announced a strategic global co-development agreement for Infudopa SubC. This innovative drug-device therapy offers a wearable, user-friendly alternative for advanced Parkinson’s disease (PD) patients, aiming to improve independence and quality of life.
Infudopa SubC delivers a continuous levodopa-carbidopa infusion via a subcutaneous wearable belt pump, designed specifically for patients whose motor symptoms are no longer well-managed by oral medications. As PD affects over 10 million people globally—with numbers expected to double by 2050—this therapy addresses the growing need for effective, practical treatments in advanced stages of the disease.
Under the agreement, Neuraxpharm will co-develop and hold exclusive commercialization rights in Europe, other markets where it operates directly, and will partner for territories like the U.S. and Japan. Neuraxpharm CEO Dr. Jörg-Thomas Dierks highlighted the collaboration as a major step toward innovative Parkinson’s care, describing Infudopa SubC as a “life-changing solution” for patients.
Dizlin CEO Björn Velin expressed confidence in accelerating the therapy’s market entry, emphasizing the goal of enhancing life quality and functioning for patients with advanced PD.
This partnership builds on Neuraxpharm’s commitment to CNS innovation, following its recent entry into digital health with a wearable epilepsy seizure prediction device. The collaboration with Dizlin represents a significant advance in integrating pharmaceutical and medical technology to meet critical unmet needs in neurological care.